Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000648409 | SCV000770229 | uncertain significance | Developmental and epileptic encephalopathy, 12 | 2021-10-20 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. This variant has not been reported in the literature in individuals affected with PLCB1-related conditions. This variant is present in population databases (rs191106606, ExAC 0.02%). This sequence change replaces isoleucine with valine at codon 41 of the PLCB1 protein (p.Ile41Val). The isoleucine residue is weakly conserved and there is a small physicochemical difference between isoleucine and valine. |